What question did this study set out to answer?

This study aims to evaluate the long-term outcomes of a chemotherapy-free regimen utilizing blinatumomab and ponatinib in adults diagnosed with Ph+ B-ALL.

May 29, 2026Journal of Clinical Oncology

Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.

View Full Paper

Ask AI

Bookmark

Authors

LNLewis NasrThe University of Texas MD Anderson Cancer Center HGHannah GoulartThe University of Texas MD Anderson Cancer Center NSNicholas James ShortThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Randomized trial evaluates long-term efficacy of blinatumomab and ponatinib in newly diagnosed Ph+ B-ALL, suggesting effective alternatives to SCT.

Key Points

This study aims to evaluate the long-term outcomes of a chemotherapy-free regimen utilizing blinatumomab and ponatinib in adults diagnosed with Ph+ B-ALL.
Patients aged ≥18 years with Ph+ B-ALL received up to 5 cycles of blinatumomab alongside daily ponatinib, with adjustments based on response.
The protocol included an amendment for high-dose methotrexate and cytarabine for patients with elevated white blood cell counts.
Complete molecular response and measurable residual disease were assessed using next-generation sequencing.
The objective response rate was 96%, with a complete remission rate of 95%.
After a median follow-up of 3 years, event-free survival and overall survival rates are 79% and 89%, respectively.
Relapse risk was significantly higher for patients with baseline white blood cell counts greater than 70 x10^9/L, with a cumulative incidence of 31%.

Cite This Study

Nasr et al. (2026) studied this question.

synapsesocial.com/papers/6a192dbbfab5b468c4416a42 https://doi.org/10.1200/jco.2026.44.16_suppl.6514

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates long-term efficacy of blinatumomab and ponatinib in newly diagnosed Ph+ B-ALL, suggesting effective alternatives to SCT.

Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.

Discussion

Member takes

Implication

Key Points

Cite This Study

Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider